Posted by Michael Wonder on 16 Aug 2025
MHRA approves teplizumab to delay progression of type 1 diabetes
14 August 2025 - The MHRA has today approved teplizumab (Tzield) to delay the onset of stage 3 type 1 diabetes mellitus by an average of three years in adults and children aged 8 years and older with stage 2 type 1 diabetes mellitus.
Teplizumab is the UK’s first ever approved immunotherapy for type 1 diabetes mellitus.
